article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

4 The definition has since evolved and expanded to include molecular signatures of pharmacodynamics and therapeutic response. Novel mechanisms of action associated with CGTs naturally create dosing effects that apply in very different ways than with traditional small molecule pharmacotherapies. 21(10):3517. Rodrigues AD.

article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

DrugBaron

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

Small molecule GLP1s? My take is definitively no, though they will likely increasingly be used in early stages (F0-F2) and as backbones to combination therapy. Whether it’s small molecules to target the incretins (GLP1R ± GIPR), targeting well-validated signaling nodes in I&I (e.g.,

article thumbnail

The Active Ingredient Stands Alone

FDA Law Blog: Biosimilars

To set the stage for this case, we need to go back to March 2020 , when a new definition of “biological product” threw the world of protein products into a tizzy. As a result of the Biologics Price Competition and Innovation Act (BPCIA) passed in 2010, the definition of a “biological product” expanded to include “proteins.”

FDA 95
article thumbnail

Leadership in the Age of Stacks

LifeSciVC

This essay takes up those questions, not to provide definitive answers, but to explore the contours of a new leadership landscape. Not because they’re definitive, but because they feel aligned with the realities biotech leaders now face. One team might be working on a cell therapy, another on RNA, another on small molecules.

article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

Because this programme is still in early research, we are not at a point we can say we definitely know what it is going to work best in setting X or setting Y. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

article thumbnail

Natural Intelligence?

Molecular Design

My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post.